vs
Side-by-side financial comparison of Anterix Inc. (ATEX) and Bolt Biotherapeutics, Inc. (BOLT). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.6M, roughly 1.6× Anterix Inc.). Bolt Biotherapeutics, Inc. runs the higher net margin — -265.2% vs -419.6%, a 154.4% gap on every dollar of revenue. Over the past eight quarters, Anterix Inc.'s revenue compounded faster (11.7% CAGR vs -31.2%).
Anterix Inc. is a U.S.-headquartered wireless communications company that owns licensed 900 MHz spectrum assets, providing secure, dedicated private broadband network solutions for critical infrastructure operators including electric utilities, public safety agencies, and transportation providers. Its primary market is North America, supporting clients requiring highly reliable connectivity for mission-critical operations.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
ATEX vs BOLT — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.5M |
| Net Profit | $-6.6M | $-6.6M |
| Gross Margin | — | — |
| Operating Margin | -576.0% | -283.4% |
| Net Margin | -419.6% | -265.2% |
| Revenue YoY | 0.4% | — |
| Net Profit YoY | -185.6% | 58.4% |
| EPS (diluted) | $-0.35 | $-9.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.5M | ||
| Q3 25 | $1.6M | $2.2M | ||
| Q2 25 | $1.4M | $1.8M | ||
| Q1 25 | $1.4M | $1.2M | ||
| Q4 24 | $1.6M | $0 | ||
| Q3 24 | $1.6M | $1.1M | ||
| Q2 24 | $1.5M | $1.3M | ||
| Q1 24 | $1.3M | $5.3M |
| Q4 25 | $-6.6M | $-6.6M | ||
| Q3 25 | $53.5M | $-7.1M | ||
| Q2 25 | $25.2M | $-8.6M | ||
| Q1 25 | $9.2M | $-11.0M | ||
| Q4 24 | $7.7M | $-15.9M | ||
| Q3 24 | $-12.8M | $-15.2M | ||
| Q2 24 | $-15.5M | $-21.2M | ||
| Q1 24 | $-9.4M | $-10.8M |
| Q4 25 | -576.0% | -283.4% | ||
| Q3 25 | — | -355.1% | ||
| Q2 25 | — | -510.5% | ||
| Q1 25 | — | -991.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -846.6% | -1441.1% | ||
| Q2 24 | -984.4% | -1772.3% | ||
| Q1 24 | -834.2% | -324.1% |
| Q4 25 | -419.6% | -265.2% | ||
| Q3 25 | 3449.5% | -329.4% | ||
| Q2 25 | 1775.7% | -474.6% | ||
| Q1 25 | 662.9% | -903.4% | ||
| Q4 24 | 492.3% | — | ||
| Q3 24 | -823.1% | -1330.1% | ||
| Q2 24 | -1018.0% | -1662.4% | ||
| Q1 24 | -746.9% | -205.0% |
| Q4 25 | $-0.35 | $-9.38 | ||
| Q3 25 | $2.86 | $-3.72 | ||
| Q2 25 | $1.35 | $-4.46 | ||
| Q1 25 | $0.51 | $-0.29 | ||
| Q4 24 | $0.41 | $-13.73 | ||
| Q3 24 | $-0.69 | $-7.93 | ||
| Q2 24 | $-0.84 | $-11.12 | ||
| Q1 24 | $-0.51 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.5M | $27.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $236.0M | $26.5M |
| Total Assets | $417.0M | $56.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.5M | $27.5M | ||
| Q3 25 | $39.1M | $31.9M | ||
| Q2 25 | $41.4M | $34.8M | ||
| Q1 25 | $47.4M | $38.8M | ||
| Q4 24 | $28.8M | $47.3M | ||
| Q3 24 | $43.1M | $53.8M | ||
| Q2 24 | $51.7M | $73.7M | ||
| Q1 24 | $60.6M | $91.3M |
| Q4 25 | $236.0M | $26.5M | ||
| Q3 25 | $240.3M | $32.1M | ||
| Q2 25 | $184.8M | $38.8M | ||
| Q1 25 | $156.6M | $46.8M | ||
| Q4 24 | $144.7M | $57.2M | ||
| Q3 24 | $139.1M | $72.0M | ||
| Q2 24 | $148.8M | $85.9M | ||
| Q1 24 | $161.0M | $104.2M |
| Q4 25 | $417.0M | $56.7M | ||
| Q3 25 | $420.4M | $65.1M | ||
| Q2 25 | $359.6M | $75.5M | ||
| Q1 25 | $333.1M | $85.9M | ||
| Q4 24 | $326.7M | $99.6M | ||
| Q3 24 | $317.2M | $109.3M | ||
| Q2 24 | $321.1M | $124.2M | ||
| Q1 24 | $324.9M | $142.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.3M | $-7.2M |
| Free Cash FlowOCF − Capex | $-8.3M | — |
| FCF MarginFCF / Revenue | -526.4% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.3M | $-7.2M | ||
| Q3 25 | $1.4M | $-9.7M | ||
| Q2 25 | $-3.1M | $-9.6M | ||
| Q1 25 | $-16.6M | $-13.4M | ||
| Q4 24 | $-7.7M | $-14.4M | ||
| Q3 24 | $-2.6M | $-14.0M | ||
| Q2 24 | $-2.4M | $-16.1M | ||
| Q1 24 | $6.1M | $-16.8M |
| Q4 25 | $-8.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-16.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.7M | $-14.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | $6.1M | — |
| Q4 25 | -526.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -1195.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -173.4% | -1227.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | 484.1% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 2.6% | 3.6% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 3.2% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | -0.12× | — | ||
| Q1 25 | -1.80× | — | ||
| Q4 24 | -1.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
